Jennifer S Albrecht1, Bilal Khokhar2, Françoise Pradel2, Michelle Campbell2, Jacqueline Palmer3, Ilene Harris4, Francis Palumbo2. 1. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Maryland, USA. 2. Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy. 3. Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy; Health Economics & Outcomes Research: Critical Care, Novartis Pharmaceuticals, Basel, Switzerland. 4. Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy; Health Division, IMPAQ International, LLC, Columbia, Maryland, USA.
Abstract
OBJECTIVES: Use of patient provider agreements (PPAs) is increasing, yet there is limited evidence on the effectiveness of PPAs to prevent prescription opioid misuse and diversion, and few guidelines for providers. We conducted eight focus groups to understand patient and prescriber perceptions of PPAs. METHODS: We recruited 40 patients who had been asked to sign a PPA and 40 prescribers who had administered at least one PPA. We developed topic guides for the two groups based on prior literature. Focus groups were audio-recorded and transcribed verbatim. Two investigators independently performed the content analysis of the transcripts and reached consensus on recurring themes. KEY FINDINGS: PPA use varied according to physician specialty. General practitioners used PPAs the least but reported increasing pressure from liability insurers to use them. Many patients reported signing a PPA in the emergency room of a hospital. Prescribers and patients reported a lack of understanding among patients concerning the purpose and content of the PPA. Prescribers questioned the legal status of the PPA, while patients believed that the PPA was a legal document intended to protect prescribers. Patients and prescribers valued PPA content items differently, although both groups agreed that signing a PPA would not prevent opioid misuse. CONCLUSIONS: We identified several themes concerning the administration, content, effectiveness and utility of PPAs that highlight areas of research to improve PPAs. We also describe trends requiring further investigation. Understanding content of importance to patients will facilitate the development of a patient-centred PPA.
OBJECTIVES: Use of patient provider agreements (PPAs) is increasing, yet there is limited evidence on the effectiveness of PPAs to prevent prescription opioid misuse and diversion, and few guidelines for providers. We conducted eight focus groups to understand patient and prescriber perceptions of PPAs. METHODS: We recruited 40 patients who had been asked to sign a PPA and 40 prescribers who had administered at least one PPA. We developed topic guides for the two groups based on prior literature. Focus groups were audio-recorded and transcribed verbatim. Two investigators independently performed the content analysis of the transcripts and reached consensus on recurring themes. KEY FINDINGS:PPA use varied according to physician specialty. General practitioners used PPAs the least but reported increasing pressure from liability insurers to use them. Many patients reported signing a PPA in the emergency room of a hospital. Prescribers and patients reported a lack of understanding among patients concerning the purpose and content of the PPA. Prescribers questioned the legal status of the PPA, while patients believed that the PPA was a legal document intended to protect prescribers. Patients and prescribers valued PPA content items differently, although both groups agreed that signing a PPA would not prevent opioid misuse. CONCLUSIONS: We identified several themes concerning the administration, content, effectiveness and utility of PPAs that highlight areas of research to improve PPAs. We also describe trends requiring further investigation. Understanding content of importance to patients will facilitate the development of a patient-centred PPA.
Authors: Richard Payne; Evan Anderson; Robert Arnold; Lennie Duensing; Aaron Gilson; Carmen Green; Carlton Haywood; Steve Passik; Ben Rich; Lisa Robin; Nick Shuler; Myra Christopher Journal: Am J Bioeth Date: 2010-11 Impact factor: 11.229
Authors: Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski Journal: J Pain Date: 2009-02 Impact factor: 5.820
Authors: Michelle S Keller; Alma Jusufagic; Teryl K Nuckols; Jack Needleman; MarySue V Heilemann Journal: Subst Use Misuse Date: 2021-05-22 Impact factor: 2.164
Authors: Jordana Laks; Daniel P Alford; Krupa Patel; Margaret Jones; Emily Armstrong; Katherine Waite; Lori Henault; Michael K Paasche-Orlow Journal: J Gen Intern Med Date: 2021-01-08 Impact factor: 5.128
Authors: Celia Oreja-Guevara; Stanca Potra; Birgit Bauer; Diego Centonze; Maria-Paz Giambastiani; Gavin Giovannoni; Jürg Kesselring; Dawn Langdon; Sarah A Morrow; Jocelyne Nouvet-Gire; Maija Pontaga; Peter Rieckmann; Sven Schippling; Nektaria Alexandri; Jane Shanahan; Heidi Thompson; Pieter Van Galen; Patrick Vermersch; David Yeandle Journal: Adv Ther Date: 2019-09-05 Impact factor: 3.845